Clin­i­cal tri­al brand­ing? Biotechs and phar­mas mi­grate name and iden­ti­ty strate­gies even ear­li­er

Brand­ing is mov­ing more and more down­stream in­to clin­i­cal tri­als. Biotech and phar­ma com­pa­nies are think­ing about drug brand prod­uct names and iden­ti­ties much soon­er in the de­vel­op­ment process, but there’s al­so an­oth­er trend brew­ing in ear­ly mar­ket­ing strate­gies — clin­i­cal tri­al brand­ing.

With drug de­vel­op­ment fo­cus­ing in on more rare dis­eases and small­er pa­tient pop­u­la­tions, bio­phar­mas are fight­ing for mind­share and look­ing for a way to stand out to pa­tients and health­care pro­fes­sion­als. And that’s where Phase II clin­i­cal tri­al brand­ing is start­ing to fire up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.